Reuters logo
a month ago
BRIEF-I'rom Group unit ID Pharma concludes iPS cell generation technology licensing agreement with UK-based Axol Bioscience
July 11, 2017 / 9:44 AM / a month ago

BRIEF-I'rom Group unit ID Pharma concludes iPS cell generation technology licensing agreement with UK-based Axol Bioscience

July 11 (Reuters) - I'rom Group Co Ltd

* Says co's wholly owned unit, ID Pharma, concluded an iPS cell generation technology licensing agreement with UK-based Axol Bioscience Ltd

* Says unit grants non-exclusive rights of iPS cell related research, sales and service and sublicense rights to Axol Bioscience Ltd

* Says unit will receive upfront payments, iPS cell sales and service related income and royalty from Axol Bioscience Ltd

Source text in Japanese: goo.gl/RsB4rr

Further company coverage: (Beijing Headline News)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below